Bradley Bus, PA
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 357 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 27.9% of the total. Reporting peaked in 2023 at $2,819 and has fallen 95.3% since, to $134 in 2025.
Across 357 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$582
- AstraZeneca$481
- Boehringer Ingelheim$383
- Amgen$334
- Pfizer$334
- plus $2K from 31 others
What the payments were for
- Food & beverage$5,965100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 93 | $1,664 |
| Novo Nordisk | 43 | $582 |
| AstraZeneca | 31 | $481 |
| Boehringer Ingelheim | 24 | $383 |
| Amgen(2 entities) | 15 | $334 |
| Pfizer | 21 | $334 |
| Lilly USA, LLC | 18 | $256 |
| Johnson & Johnson(2 entities) | 14 | $205 |
| Idorsia Pharmaceuticals US Inc | 13 | $189 |
| Astellas Pharma US Inc | 6 | $140 |
| Bayer | 8 | $139 |
| Corcept Therapeutics | 9 | $139 |
| GSK | 7 | $127 |
| Bioventus LLC | 4 | $90 |
| Avanir Pharmaceuticals, Inc. | 5 | $86 |
| Novartis | 5 | $81 |
| Dexcom, Inc. | 2 | $77 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 4 | $71 |
| Esperion Therapeutics, Inc. | 4 | $69 |
| Merck | 3 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Ironwood Pharmaceuticals, Inc | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Eisai Inc. | 2 | $29 |
| Vertex | 1 | $29 |
| Clarus Therapeutics Inc. | 1 | $25 |
| Lucid Diagnostics Inc. | 1 | $24 |
| Nalu Medical, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Evolution Surgical, Inc | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $7 |
How this compares
$5,965 in reported general payments places this provider in the 85th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $54,561 |
| EliquisApixaban | 34 | $32,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,617 |
| XareltoRivaroxaban | 12 | $6,684 |
| Atorvastatin Calcium | 131 | $1,568 |
| Gabapentin | 53 | $1,474 |
| Tamsulosin Hcl | 65 | $1,372 |
| Rosuvastatin Calcium | 54 | $1,145 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,114 |
| Levothyroxine Sodium | 81 | $1,043 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,019 |
| Omeprazole | 44 | $764 |
| Lisinopril | 96 | $746 |
| Losartan Potassium | 53 | $646 |
| Pravastatin Sodium | 23 | $526 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $383 | $54,56135 claims |
| PfizerEliquis | $334 | $32,22134 claims |
| GSKTrelegy Ellipta | $127 | $9,61711 claims |
| Johnson & JohnsonXarelto | $205 | $6,68412 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $41318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 250 medical providers in Nevada.
Other medical in Reno
- Ashley OwensReno$7K
- Christine BurnsReno$7K
- Brian DouglasReno$7K
- Sarah GutierrezReno$6K
- Melissa ShelleyReno$6K
- Gretchen GoicoecheaReno$5K
- Nicholas BeaudetteReno$4K
- Shaylee NystromReno$4K
- Sheila QuinnReno$4K
- Carla ChongReno$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.